Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome.
OBJECTIVE
To compare the pharmacokinetics of cyclosporine in patients with either cystic fibrosis or Eisenmenger's syndrome.


METHODS
Patients in the study were heart and lung transplant candidates with either cystic fibrosis (n = 6) or Eisenmenger's syndrome (n = 5), as well as patients who received heart and lung transplantation for either cystic fibrosis (n = 13) or Eisenmenger's syndrome (n = 7). This was no experimental pharmacokinetic study in transplant candidates and an exploratory population pharmacokinetic study in transplant recipients.


RESULTS
Patients with cystic fibrosis showed higher blood cyclosporine clearance, higher apparent oral clearance, shorter mean residence time, and more erratic absorption. The coefficient of variation of pharmacokinetic parameters was higher in patients with cystic fibrosis. There were no significant differences in metabolite indexes between the two groups of patients after either oral or intravenous administration. A significant negative correlation was found between cyclosporine clearance and hematocrit (r = 0.81 [95% confidence interval, -0.95 to -0.4.1]). Dose-normalized predose blood concentration measurements were lower in patients with cystic fibrosis after transplantation. There was a significant correlation between hematocrit and log dose-normalized cyclosporine concentration (r = 0.40 [95% confidence interval, 0.30 to 0.49]). The total daily dose per 100 ng/ml trough blood concentration required was estimated to be 2.36 times (95% confidence interval, 1.96 to 2.84) higher in patients with cystic fibrosis.


CONCLUSIONS
Cyclosporine pharmacokinetics is more variable in patients with cystic fibrosis. The difference in cyclosporine clearance between the two groups is accounted for by differences in binding in blood rather than metabolism. The findings suggest that patients with cystic fibrosis could be conservatively given initial oral doses that are 1.5 times higher than those for patients who receive transplants because of Eisenmenger's syndrome.
Tan
K K
KK
Clinical Pharmacology Unit, Addenbrooke's Hospital, Cambridge, England.
Trull
A K
AK
Hue
K L
KL
Best
N G
NG
Wallwork
J
J
Higenbottam
T W
TW
D000328:Adult; D016572:Cyclosporine / Q000493:pharmacokinetics*; D003550:Cystic Fibrosis / Q000097:blood* / Q000601:surgery; D004541:Eisenmenger Complex / Q000097:blood* / Q000601:surgery; D005260:Female; D016041:Heart-Lung Transplantation / Q000502:physiology*; D006801:Humans; D008297:Male; D008954:Models, Biological; D013223:Statistics as Topic
D016572:Cyclosporine